Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
IPSC
IPSC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IPSC News
Momentum in iPSC-Derived NK Cells Clinical Trials: 12+ Companies Innovate
Feb 16 2026
Newsfilter
Why Century Therapeutics (IPSC) Is an Excellent Option for Value Investors
Dec 09 2025
NASDAQ.COM
Century Therapeutics Appoints New Directors to Accelerate iPSC Therapy Development
Dec 09 2025
Newsfilter
Century Therapeutics Unveils New Beta Islet Initiative for Type 1 Diabetes
Nov 13 2025
Newsfilter
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Jul 21 2025
NASDAQ.COM
The Top Corporate Board Directors
May 19 2025
WSJ
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
May 16 2025
NASDAQ.COM
Guggenheim Reiterates Buy on Century Therapeuticsto Buy
Mar 28 2025
Benzinga
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
Mar 24 2025
Benzinga
Guggenheim Maintains Buy on Century Therapeutics, Lowers Price Target to $5
Mar 21 2025
Benzinga
Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $2
Mar 20 2025
Benzinga
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
Jan 21 2025
Newsfilter
Piper Sandler Maintains Overweight on Century Therapeutics, Lowers Price Target to $4
Dec 30 2024
Benzinga
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)
Dec 18 2024
Business Insider
Clear Street Launches Healthcare & Biotechnology Equity Research
Dec 17 2024
Newsfilter
Century Therapeutics Faces Termination of BMS Agreement
Dec 13 2024
Business Insider
Show More News
